Summit Therapeutics Inc. — Form 8-K
Filed September 28, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
AstraZeneca Holdings B.V. is investing $2.0 billion in Summit Therapeutics through purchase of approximately 108,955 shares of Class A Convertible Preferred Stock convertible into common stock at a 1:1,000 ratio, implying a per-share price of $18.36 (VWAP plus 10%). The transaction includes a clinical collaboration agreement to evaluate ivonescimab combined with AstraZeneca's sonesitatug vedotin in gastrointestinal cancers, plus a non-binding MOU for future trials combining ivonescimab with AstraZeneca's ADC portfolio. Closing expected by end of week.
Why this rating
Large strategic capital infusion ($2B ≈ 80% of company market cap) validates pipeline, funds R&D, provides non-dilutive near-term benefit to existing shareholders; creates pharma partnership de-risking clinical development.
Tradability signal
NO TRADE
No trade: positive news with only -1.8% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.38% over 4 hrs, n=124). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $15.48 | +10 min · unknown $16.65 ▲ 7.55% | +30 min · unknown $16.56 ▲ 6.98% | +1 hr · unknown $16.44 ▲ 6.20% | +4 hrs · unknown $16.27 ▲ 5.10% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.